Chronic Hepatitis B Clinical Trial
Official title:
The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg(I-Cure-3X)
HBeAg-negative chronic hepatitis B (CHB) patients with low Level HBsAg were enrolled. After
giving informed consent, patients were treated with nucleoside analog(s) (NAs) once a day and
weekly subcutaneous injections of peginterferon alfa-2a 180 micrograms/week or peginterferon
alfa-2b 180 micrograms/week for 12 weeks. At week 12, the decrease of HBsAg was evaluated.
①If the decrease of HBsAg is more than 50% compared to baseline level. NAs was stopped,
patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or
peginterferon alfa-2b 180 micrograms/week. Treatment endpoint was HBsAg loss(＜0.05 IU/ mL).
Depending on the decline of HBsAg level, treatment was either continued for a prolonged
period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.
After treatment, all patients were followed up for 48 weeks.
②If the decrease of HBsAg is less than 50% compared to baseline level. The combination
therapy of NAs and peginterferon alfa was extended to week 24. Then, the decrease of HBsAg
was evaluated again.
If the decrease of HBsAg is more than 50% compared to baseline level. NAs was stopped,
patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or
peginterferon alfa-2b 180 micrograms/week. Treatment endpoint was HBsAg loss(＜0.05 IU/mL).
Depending on the decline of HBsAg level, treatment was either continued for a prolonged
period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.
After treatment, all patients were followed up for 48 weeks.
If the decrease of HBsAg is less than 50% compared to baseline level. Peginterferon alfa was
stopped, patients were treated with NAs once a day and then followed up for 48 weeks.
Patients who maintained the original NAs treatment served as a control group.
It is estimated that more than 400 million people are infected with hepatitis B virus (HBV)
globally. HBeAg-negative CHB patients with low Level HBsAg were enrolled in the out-patient
department of Third Affiliated Hospital of Sun Yat-sen University and Wuhan Union Hospital.
All of them were HBsAg positive and anti-HBs negative for more than 6 months with HBV DNA<100
IU/mL and HBsAg levels <1000 IU/mL. All patients did not have other liver diseases and
contraindications for interferon therapy. After giving informed consent, patients were
treated with nucleoside analog(s) (NAs) once a day and weekly subcutaneous injections of
peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 180 micrograms/week for 12
weeks. At week 12, the decrease of HBsAg was evaluated.
①If the decrease of HBsAg is more than 50% compared to baseline level. NAs was stopped,
patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or
peginterferon alfa-2b 180 micrograms/week. Treatment endpoint was HBsAg loss(＜0.05 IU/ mL).
Depending on the decline of HBsAg level, treatment was either continued for a prolonged
period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.
After treatment, all patients were followed up for 48 weeks.
②If the decrease of HBsAg is less than 50% compared to baseline level. The combination
therapy of NAs and peginterferon alfa was extended to week 24. Then, the decrease of HBsAg
was evaluated again.
If the decrease of HBsAg is more than 50% compared to baseline level. NAs was stopped,
patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or
peginterferon alfa-2b 180 micrograms/week. Treatment endpoint was HBsAg loss(＜0.05 IU/mL).
Depending on the decline of HBsAg level, treatment was either continued for a prolonged
period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.
After treatment, all patients were followed up for 48 weeks.
If the decrease of HBsAg is less than 50% compared to baseline level. Peginterferon alfa was
stopped, patients were treated with NAs once a day and then followed up for 48 weeks.
The use of other immune suppressive or regulatory drugs and other antiviral drugs was
prohibited during the course of the study. In this study, HBsAg loss(＜0.05 IU/mL) was defined
as treatment endpoint. Anti-HBs positive(＞10 milli-International unit)(mIU/mL) was defined as
seroconversion.
Patients who maintained the original NAs treatment served as a control group.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04496882 -
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
|
Phase 4 | |
| Completed |
NCT04083716 -
A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
|
Phase 1 | |
| Not yet recruiting |
NCT03038802 -
A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
|
Phase 1/Phase 2 | |
| Completed |
NCT05310487 -
Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects
|
Phase 1 | |
| Recruiting |
NCT06070051 -
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
|
Phase 1 | |
| Terminated |
NCT05001022 -
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
|
Phase 1 | |
| Recruiting |
NCT04139850 -
The Establishment of Korean Hepatitis B Patients Cohort
|
||
| Recruiting |
NCT05343481 -
Efficacy of VTP-300 in Chronic Hepatitis B Infection
|
Phase 2 | |
| Not yet recruiting |
NCT05490836 -
Functional Cure Rate of Peg-IFNα-2b Combined With TAF in HBeAg Negative CHB Patients
|
N/A | |
| Recruiting |
NCT04543565 -
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
|
Phase 3 | |
| Active, not recruiting |
NCT02894918 -
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
|
Phase 4 | |
| Not yet recruiting |
NCT02793791 -
Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients
|
N/A | |
| Recruiting |
NCT02287857 -
Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B
|
N/A | |
| Recruiting |
NCT01965418 -
A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial
|
Phase 4 | |
| Recruiting |
NCT01491295 -
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients
|
Phase 4 | |
| Terminated |
NCT01872988 -
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
|
Phase 3 | |
| Recruiting |
NCT01487876 -
Efficacy and Safety of Dual-plasmid Hepatitis B Virus DNA Vaccine in Chronic Hepatitis B Patients
|
Phase 2 | |
| Completed |
NCT01531166 -
A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon
|
N/A | |
| Not yet recruiting |
NCT01436539 -
Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients
|
Phase 4 | |
| Recruiting |
NCT01360879 -
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
|
N/A |